The James Lind Alliance and I

Uploaded on


More in: Technology , Education
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
No Downloads


Total Views
On Slideshare
From Embeds
Number of Embeds



Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

    No notes for slide


  • 1. The James Lind Alliance - and I Lester Firkins Priority setting for Systematic Reviews Conference US Cochrane Center 11th July 2008
  • 2. Introduction
    • Who am I and how did I get here?
    • What did the journey teach me?
    • Is this the way research should be?
    • There is another way …
      • The James Lind Alliance
  • 3. Who is Lester Firkins?
    • Middle aged, middle class, white, male
    • 35 years in UK banking industry
      • Conventional
      • Content with rules and structure
      • Performance and achievement driven
    • Fairly well read - with a broad understanding of most things
      • Medicine and research is looked after by others - and always in my best interest
      • My money is well spent
  • 4. My journey starts here …
    • Ellis Firkins
    • First Class Honours graduate in Design Technology
    • Teacher at major UK public school
    • Died on 1 March 2001 from variant Creutzfeld-Jacob Disease (vCJD)
  • 5. My journey
    • Chair, Human BSE Foundation
    • Co-chair, Prion-1 Clinical Trial, Medical Research Council (MRC)
    • Co-chair, New Therapies Scrutiny Group
    • Member, National Institute of Clinical Excellence (NICE)
    • Chair, James Lind Alliance
  • 6. Consumer workshop on CJD trials
    • MRC and Department of Health (DH)
    • “ To enable consumer understanding of clinical trial design and provide an opportunity for consumers and researchers to share ideas”
      • Strong support for trial design
      • Strong support for collecting research
      • Need for design to be flexible to accommodate emerging therapies
      • Acknowledgement that it is good to be involved
  • 7. MRC Prion1 Clinical Trial
    • 2004 - A partially randomised patient preference trial to evaluate the activity and safety of quinacrine in human prion disease
    • Trial Steering Committee
      • Sir Iain Chalmers and Lester Firkins
    • Why Quinacrine?
      • Systematic review
      • Daily Newspaper
  • 8. New Therapies Scrutiny Group
    • MRC Committee to look for emerging therapies
    • Co- Chairs;
      • Sir Michael Rawlins and Lester Firkins
    • Recommendations for future research funding and effort
    • Theatre of conflict and dysfunction
  • 9. The Missing Element
    • Systematic Review
      • ..of treated and untreated patients with human prion disease
      • Published in Spring 2008
      • Results too late to influence Prion-1 (now closed)
      • Flupirtine may have been a wiser option than Quinacrine (but no media lobby)
    • Clear evidence that publication had been hindered by vested interests
  • 10.
    • A systematic review of therapeutic interventions in human prion disease
    Project Group Lesley Stewart 1 , Larysa Rydzewska 1 Geraldine Keogh 2 , Richard Knight 3 Advisory Group Iain Chalmers 4 , Lester Firkins 5 , Sarah Walker 1 1 MRC Clinical Trials Unit, 2 National Prion Clinic, 3 National CJD Surveillance Unit, 4 James Lind Library, 5 MRC New Therapies Scrutiny Group
  • 11. The Unspeakable Element
    • Minimal international collaboration
    • Academic jealousies
      • Directive from Chief Medical Officer on how UK institutions must work together
      • Monthly meeting between Heads of Research Units to ensure that they work together
  • 12. The Isolated Element
    • Pentosan polysulphate
    • Promoted by one man looking after his son
    • 2003 - High Court agreement for (unapproved) therapy to be administered
    • 3 patients still alive - longer than “normal”
    • No coordinated monitoring whatsoever
    • Mutual distrust leading to complete lack of learning and patient care
  • 13. What have I seen?
    • A hugely expensive trial can be set up with no formal understanding of what has been done in the past
    • Media can influence decisions more than grounded knowledge
    • Unless potential therapies find a “friend” their application can be frustrated
    • “ Patient First” promoted as an aspiration - but not if it conflicts with academic interests
    • Dysfunction and jealousies betray the interests of patients and their families
  • 14. What about a formal programme? One option
    • James Lind Alliance
  • 15. The James Lind Alliance
    • Formed in 2004 by;
      • Royal Society of Medicine
      • James Lind Library
      • INVOLVE (formerly Consumers in NHS Research)
    • Funded by DH and MRC till 2010, to see if it works
    • Tackling treatment uncertainties - together (Patients and Clinicians)
  • 16. What are our objectives
    • To support “Working Partnerships” of patients (and their carers) and clinicians to prioritise “Treatment Uncertainties” into a list for research funders to address
    • To support and raise the profile of proper involvement for all people with an interest in medical research
    • To gain evidence on how best to prioritise with Patients and Clinicians collaborating
  • 17. JLA - working partnerships
    • Asthma
      • JLA approached by British Thoracic Society and Asthma UK
      • Worked together over many months.
        • Harvesting Uncertainties
        • Checking and verifying “known unknowns”
        • Entering into a standard database “DUETs”
        • Priority setting meetings - top ten list agreed
      • What Next
        • BMJ article in preparation
        • Systematic review of inhaled and oral steroids commissioned
        • HTA standing ready!
  • 18. JLA - working partnerships
    • Urinary Incontinence
      • JLA approached by Incontact and University of Aberdeen (Cochrane)
      • Approached 30 related organisations - of which 21 have joined as formal partners
      • Currently Harvesting Uncertainties - to conclude by 30th June
      • Data cleaning and priority setting by December 2008
    • Schizophrenia
    • Vitiligo
    • Diabetes
  • 19. NIHR HTA Annual Report 2007
    • “ The HTA programme encourages patient involvement at every stage and it is continuing to take this forward and develop it”
    • “… . the HTA programme is working with the JLA to capture those priorities suitable for HTA research”.
  • 20. WIFM -Patients
    • Real involvement in their problems
    • Share of Voice
    • Someone showing an interest
    • Participation
  • 21. WIFM Clinicians
    • Opportunity to share their unique knowledge and perspective
    • Getting their personal and professional concerns over “Uncertainties” acknowledged and addressed
  • 22. WIFM Researchers
    • Ideas that make a real difference
    • Support in the ethics process
    • Participation within the research itself
    • Advocates and disseminators
    • Seeing the difference in people’s eyes
  • 23. Will the JLA work?
    • Three years to find out!
    • It needs to be seen as invaluable at every level
    • It needs to find a permanent home
    • It may stimulate others to do something better
  • 24. Thank You
    • Delighted and proud to be able to tell my story
    • Will it make a difference?
      • Could it work in America?
        • No reason why it wouldn’t be worth a try …
    • www. lindalliance .org